120.25
4.90 (4.25%)
| 前收盘价格 | 115.35 |
| 收盘价格 | 116.02 |
| 成交量 | 1,095,691 |
| 平均成交量 (3个月) | 819,656 |
| 市值 | 8,597,874,688 |
| 市盈率 (P/E TTM) | 12.41 |
| 预期市盈率 (P/E Forward) | 9.48 |
| 价格/销量 (P/S) | 0.710 |
| 股市价格/股市净资产 (P/B) | 21.63 |
| 52周波幅 | |
| 利润日期 | 29 Oct 2025 |
| 营业毛利率 | 6.63% |
| 营业利益率 (TTM) | 13.44% |
| 稀释每股收益 (EPS TTM) | 10.08 |
| 季度收入增长率 (YOY) | 5.00% |
| 季度盈利增长率 (YOY) | -32.00% |
| 总债务/股东权益 (D/E MRQ) | 742.20% |
| 流动比率 (MRQ) | 1.25 |
| 营业现金流 (OCF TTM) | 2.34 B |
| 杠杆自由现金流 (LFCF TTM) | 1.58 B |
| 资产报酬率 (ROA TTM) | 7.04% |
| 股东权益报酬率 (ROE TTM) | 54.79% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Care Facilities (US) | 混合的 | 混合的 |
| Medical Care Facilities (全球的) | 看涨 | 混合的 | |
| 股票 | DaVita Inc. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 1.0 |
| 内部交易活动 | 0.0 |
| 价格波动 | 3.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | -0.10 |
|
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the us, and treats about 250,000 patients globally each year. Government payers dominate us dialysis reimbursement. DaVita receives about two thirds of us sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the us patients treated, they represent nearly all of the profits generated by DaVita in the us dialysis business. |
|
| 部门 | Healthcare |
| 行业 | Medical Care Facilities |
| 投资方式 | Mid Core |
| 内部持股比例 | 49.51% |
| 机构持股比例 | 48.76% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 143.00 (Barclays, 18.92%) | 保留 |
| 中 | 140.00 (16.42%) | |
| 低 | 133.00 (TD Cowen, 10.60%) | 保留 |
| 平均值 | 138.67 (15.32%) | |
| 总计 | 2 保留, 1 卖出 | |
| 平均价格@调整类型 | 123.35 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| TD Cowen | 03 Nov 2025 | 133.00 (10.60%) | 保留 | 119.05 |
| Barclays | 30 Oct 2025 | 143.00 (18.92%) | 保留 | 118.75 |
| 09 Oct 2025 | 149.00 (23.91%) | 保留 | 126.38 | |
| B of A Securities | 10 Sep 2025 | 140.00 (16.42%) | 卖出 | 132.26 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| ARWAY PAMELA M | 121.55 | - | 411 | 49,957 |
| DESOER BARBARA J | 121.55 | - | 411 | 49,957 |
| HOLLAR JASON M. | 121.55 | - | 411 | 49,957 |
| MOORE GREGORY J. | 121.55 | - | 411 | 49,957 |
| PULLIN DENNIS W | 121.55 | - | 411 | 49,957 |
| RODRIGUEZ JAVIER | - | 121.55 | -5,165 | -627,806 |
| SCHECHTER ADAM H | 121.55 | - | 411 | 49,957 |
| SCHOPPERT WENDY LEE | 121.55 | - | 411 | 49,957 |
| YALE PHYLLIS R | 121.55 | - | 411 | 49,957 |
| 累积净数量 | -1,877 | |||
| 累积净值 ($) | -228,149 | |||
| 累积平均购买 ($) | 121.55 | |||
| 累积平均卖出 ($) | 121.55 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| RODRIGUEZ JAVIER | 职员 | 15 Nov 2025 | 处理 (-) | 5,165 | 121.55 | 627,806 |
| ARWAY PAMELA M | 董事 | 15 Nov 2025 | 获得 (+) | 411 | 121.55 | 49,957 |
| DESOER BARBARA J | 董事 | 15 Nov 2025 | 获得 (+) | 411 | 121.55 | 49,957 |
| HOLLAR JASON M. | 董事 | 15 Nov 2025 | 获得 (+) | 411 | 121.55 | 49,957 |
| MOORE GREGORY J. | 董事 | 15 Nov 2025 | 获得 (+) | 411 | 121.55 | 49,957 |
| PULLIN DENNIS W | 董事 | 15 Nov 2025 | 获得 (+) | 411 | 121.55 | 49,957 |
| SCHECHTER ADAM H | 董事 | 15 Nov 2025 | 获得 (+) | 411 | 121.55 | 49,957 |
| SCHOPPERT WENDY LEE | 董事 | 15 Nov 2025 | 获得 (+) | 411 | 121.55 | 49,957 |
| YALE PHYLLIS R | 董事 | 15 Nov 2025 | 获得 (+) | 411 | 121.55 | 49,957 |
| 日期 | 类型 | 细节 |
|---|---|---|
| 14 Nov 2025 | 公告 | DaVita Inc. to Participate in Fireside Chat with Wolfe Research |
| 04 Nov 2025 | 公告 | DaVita Marks 25 Years of Innovation with Breakthrough Kidney Care Research at ASN Kidney Week 2025 |
| 29 Oct 2025 | 公告 | DaVita Inc. 3rd Quarter 2025 Results |
| 20 Oct 2025 | 公告 | DaVita Leads the Way in Evaluating Middle Molecule Clearance with Two New Initiatives |
| 13 Oct 2025 | 公告 | DaVita Inc. Schedules 3rd Quarter 2025 Investor Conference Call |
| 27 Aug 2025 | 公告 | DaVita Honors 25 Years of Clinical Advancement in Chronic Disease Care |
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合